Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shandong Xinhua Pharmaceutical Co EV-to-EBITDA?
Shandong Xinhua Pharmaceutical CoSHNXY 88 EV-to-EBITDA is 24.92 as of Aug. 21, 2026, which is 21% above its 10-year median of 20.67. GuruFocus rates SHNXY with a GF Score™ of 88/100 and a GF Value™ of $23.46. The stock has 5 warning signs investors should review. Among 739 Drug Manufacturers companies, Shandong Xinhua Pharmaceutical Co ranks worse than 69.15% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shandong Xinhua Pharmaceutical Co's enterprise value is $1,325 Mil.
Shandong Xinhua Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $53 Mil. Therefore, Shandong Xinhua Pharmaceutical Co's EV-to-EBITDA for today is 24.92.
The historical rank and industry rank for Shandong Xinhua Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
SHNXY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.69 Med: 20.67 Max: 71.7
Current: 23.15
During the past 13 years, the highest EV-to-EBITDA of Shandong Xinhua Pharmaceutical Co was 71.70. The lowest was 10.69. And the median was 20.67.
SHNXY's EV-to-EBITDA is ranked worse than 69.15% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.97
vs SHNXY: 23.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Shandong Xinhua Pharmaceutical Co (OTCPK:SHNXY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shandong Xinhua Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Shandong Xinhua Pharmaceutical Co's share price for today is $18.19.
Shandong Xinhua Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.552.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Xinhua Pharmaceutical Co EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Xinhua Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's EV-to-EBITDA falls into.
Shandong Xinhua Pharmaceutical Co's current Enterprise Value is $1,325 Mil.
Shandong Xinhua Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Xinhua Pharmaceutical Co (SHNXY) has a EV-to-EBITDA of 24.92 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shandong Xinhua Pharmaceutical Co. This is 21% above median its historical median of 20.67. Over the past decade, Shandong Xinhua Pharmaceutical Co's EV-to-EBITDA has ranged from 10.69 to 71.70. According to the industry distribution chart, Shandong Xinhua Pharmaceutical Co ranks #511 out of 739 companies in the Drug Manufacturers industry, placing it in the top 69.1%.
Is Shandong Xinhua Pharmaceutical Co's EV-to-EBITDA too high?
Shandong Xinhua Pharmaceutical Co's current EV-to-EBITDA of 24.92 is 21% above median its 10-year median of 20.67. Over the past 10 years, this metric has ranged from a low of 10.69 to a high of 71.70. The Drug Manufacturers industry median EV-to-EBITDA is 12.97. Shandong Xinhua Pharmaceutical Co's value of 24.92 is 92.1% above this industry median. Based on the distribution chart, Shandong Xinhua Pharmaceutical Co ranks #511 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shandong Xinhua Pharmaceutical Co has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Xinhua Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shandong Xinhua Pharmaceutical Co ranks #511 out of 739 companies for EV-to-EBITDA. This places Shandong Xinhua Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.97. Shandong Xinhua Pharmaceutical Co's value of 24.92 is 92.1% above this benchmark. Historically, Shandong Xinhua Pharmaceutical Co's own EV-to-EBITDA has ranged from 10.69 to 71.70 over the past decade. While the company's 10-year median is 20.67 vs. the industry median of 12.97, Shandong Xinhua Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.97, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Xinhua Pharmaceutical Co's current EV-to-EBITDA of 24.92 is 92.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shandong Xinhua Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Xinhua Pharmaceutical Co's current EV-to-EBITDA is 24.92, which is 21% above median its own 10-year median of 20.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Xinhua Pharmaceutical Co stock overvalued right now?
Shandong Xinhua Pharmaceutical Co (SHNXY) has a current EV-to-EBITDA of 24.92. The stock's GF Value™ is $23.46, compared to a current price of $18.19 — trading 22.5% below its estimated fair value. The current EV-to-EBITDA is 24.92, which is 21% above median its 10-year median of 20.67 and 92.1% above the Drug Manufacturers industry median of 12.97. Shandong Xinhua Pharmaceutical Co's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shandong Xinhua Pharmaceutical Co (SHNXY), the current EV-to-EBITDA is 24.92 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Xinhua Pharmaceutical Co (SHNXY) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co stock appears to be undervalued.
The current stock price of $18.19 is trading 22.5% below its estimated GF Value™ of $23.46.
Key valuation signals for SHNXY:
EV-to-EBITDA: 24.92 (21% above median its 10-year median of 20.67)
GF Value™: $23.46 vs. price of $18.19 (22.5% below fair value)
Industry Position: 92.1% above the Drug Manufacturers median (#511 of 739)
No single metric tells the full story. See the SHNXY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
88GF Score
Get the complete analysis for SHNXY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHNXY has been successfully added to your 
